Navigation Links
TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MET/MTD/OPI/PCP/TCA/THC)

ProductsTOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MET/MTD/OPI/PCP/TCA/THC)
Company Bio-Rad Laboratories
Item TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MET/MTD/OPI/PCP/TCA/THC)
Features 
  • ComprehensiveTests for as many as 9 drugs per cassette
  • EfficientOne-step test protocol
  • FastResults in as few as 3 minutes
Description TOX/See™ is a 1-step, hand-held, point-of-care device for the qualitative detection of drug or drug metabolites in human urine.

The TOX/See device can detect up to nine of the most commonly abused drugs in 3 to 8 minutes and requires only a few drops of urine. Each TOX/See cassette is individually packaged to maximize convenience and ease of use. TOX/See features integrated test controls, easy-to-read results, and an 18-month shelf life at room temperature. The completed test card can be photocopied and archived for health and legal records.

The straightforward test protocol is designed for use by all levels of staff in hospitals, emergency departments, correctional facilities, juvenile facilities, police departments, workplaces, and recovery and rehabilitation programs.

Info Bio-Rad Laboratories
Customer Service: 1-800-2-BIORAD
Web site: http://www.bio-rad.com

Related medicine products :

1. TOX/See Rapid Urine Drug Screen Tests
2. TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MDMA/MET/MTD/OPI/PCP/THC)
3. TOX/See multi-Drugscreen Panel 9-test (PCP/BAR/AMP1000/COC/MET1000/TCA/MOR300/THC/BZO)
4. TOX/See multi-Drugscreen Panel 10-test (AMP/BAR/BZO/COC/MDMA/MET/MTD/OPI/TCA/THC)
5. TOX/See multi-Drugscreen Panel 8-test (AMP1000/COC/MOR300/THC/BZO/MET1000/MTD/BAR)
6. TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR2000/MTD)
7. TOX/See multi-Drugscreen Panel 8-test (THC/COC/AMP1000/PCP/BAR/BZO/MOR300/MTD)
8. TOX/See multi-Drugscreen Panel 5-test THC/MOR300/AMP1000/COC/BZO
9. TOX/See multi-Drugscreen Panel 5-test THC/COC/PCP/MOR300/AMP1000
10. TOX/See multi-Drugscreen Panel 5-test THC/COC/MOR300/AMP1000/MET1000
11. TOX/See multi-Drugscreen Panel 3-test AMP1000/MET1000/MDMA
Other Medicine News:Health News:AMDL Announces Guidance for FY2008 2Health News:AMDL Announces Guidance for FY2008 3Health News:AMDL Announces Guidance for FY2008 4Health News:AMDL Announces Guidance for FY2008 5Health News:Lockheed Martin Wins $24 Million IT Contract With CDC 2Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 2Health News:Symptom Screening Plus a Simple Blood Test Equals a 20 Percent Jump in Early Detection of Ovarian Cancer 3Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 2Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 3Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 4Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 5Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 6Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 7Health News:American Chemical Society's Weekly PressPac -- June 18, 2008 8Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:RxPop.com Wins 7th Annual Horizon Interactive Award 2
Breaking Medicine Technology:Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 2Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 3Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 4Sanofi Pasteur Global Dengue Vaccine Clinical Program Expanded in Latin America 5Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 2Perrigo Confirms Filing for Generic Version of Clobex(R) Spray and Announcement of Lawsuit by Galderma and Dermalogix 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 2Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 3Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 4Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 5Cantel Medical Reports 85% Increase in Net Income - EPS of $0.37 vs. $0.20 - for Quarter Ended October 31, 2009 on 10% Sales Increase 6Elsevier launches online version of the Chinese Journal of Natural Medicines 48452 1Elsevier launches online version of the Chinese Journal of Natural Medicines 48452 2Availability of diagnostic tests drive success in hospitalist run short stay units 48448 1Availability of diagnostic tests drive success in hospitalist run short stay units 48448 2HCPro Selects Vivisimo Velocity to Launch MedicareFind com 48445 1HCPro Selects Vivisimo Velocity to Launch MedicareFind com 48445 2HCPro Selects Vivisimo Velocity to Launch MedicareFind com 48445 3